Leerink Partners raises Belite Bio target to $215, keeps Outperform
Leerink Partners kept its Outperform rating on Belite Bio and lifted the target to $215 from $185, according to TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Analysts at Leerink Partners confirmed their Outperform rating on Belite Bio and raised the target from $185 to $215, a 16.2% increase.
TradingView reports that the new level implies roughly 26.5% potential movement from the November 12 close of $169.96. The rating and target data come from Benzinga.
why it matters
Analyst rating changes from individual firms usually affect the shares of a single company and rarely set the direction for the wider market. Such material is for reference only and does not constitute investment advice.
tags
instruments
sources
- Leerink Partners maintains Belite Bio at Outperform, raises price target to $215 from $185 — TradingView, 13 November 2026 at 20:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗